{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,8,3]],"date-time":"2024-08-03T18:20:53Z","timestamp":1722709253944},"reference-count":25,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2014,4,15]]},"DOI":"10.1097\/qai.0000000000000072","type":"journal-article","created":{"date-parts":[[2013,11,26]],"date-time":"2013-11-26T19:15:48Z","timestamp":1385493348000},"page":"542-550","source":"Crossref","is-referenced-by-count":4,"title":["Combination Antiretroviral Treatment for Women Previously Treated Only in Pregnancy"],"prefix":"10.1097","volume":"65","author":[{"given":"Mary A.","family":"Vogler","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura M.","family":"Smeaton","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rodney L.","family":"Wright","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sandra W.","family":"Cardoso","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jorge","family":"Sanchez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosa","family":"Infante","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.","family":"Moran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Catherine","family":"Godfrey","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lisa M.","family":"Demeter","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Victoria A.","family":"Johnson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"R2-6-20210131","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJM199611283352201","article-title":". Maternal viral load, zidovudine treatment, and the risk of transmission of human immunodeficiency virus type 1 from mother to infant. Pediatric AIDS Clinical Trials Group Protocol 076 Study Group.","volume":"335","author":"Sperling","year":"1996","journal-title":"N Engl J Med"},{"key":"R3-6-20210131","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1097\/00042560-200204150-00009","article-title":". Combination antiretroviral strategies for the treatment of pregnant HIV-1 infected women and prevention of perinatal HIV-1 transmission.","volume":"29","author":"Cooper","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R4-6-20210131","first-page":"CD008440","article-title":"Antiretroviral therapy (ART) for treating HIV infection in ART-eligible pregnant women.","volume":"17","author":"Sturt","year":"2010","journal-title":"Cochrane Database Syst Rev"},{"key":"R6-6-20210131","doi-asserted-by":"crossref","first-page":"1815","DOI":"10.1056\/NEJMoa0807252","article-title":"; NA-ACCORD Investigators. Effect of early versus deferred antiretroviral therapy for HIV on survival.","volume":"360","author":"Kitahata","year":"2009","journal-title":"N Engl J Med"},{"key":"R7-6-20210131","doi-asserted-by":"crossref","first-page":"2337","DOI":"10.1097\/00002030-200311070-00008","article-title":". Lack of persistent drug-resistant mutations evaluated within and between treatment interruptions in chronically HIV-1-infected patients.","volume":"17","author":"Papasavvas","year":"2003","journal-title":"AIDS"},{"key":"R8-6-20210131","first-page":"2381","article-title":". CD4 cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy.","volume":"18","author":"Boschi","year":"2004","journal-title":"AIDS"},{"key":"R9-6-20210131","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.1001\/jama.286.23.2981","article-title":"Structured treatment interruptions for the management of HIV infection.","volume":"286","author":"Lori","year":"2001","journal-title":"JAMA"},{"key":"R10-6-20210131","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1097\/00002030-200211220-00018","article-title":". Emergence of drug-resistant HIV-1 variants in patients undergoing structured treatment interruptions.","volume":"16","author":"Schweighardt","year":"2002","journal-title":"AIDS"},{"key":"R11-6-20210131","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1097\/00002030-200204120-00009","article-title":". Selection of drug-resistant HIV-1 mutants in response to repeated structured treatment interruptions.","volume":"16","author":"Martinez-Picado","year":"2002","journal-title":"AIDS"},{"key":"R12-6-20210131","doi-asserted-by":"crossref","first-page":"1951","DOI":"10.1097\/00002030-200110190-00006","article-title":". Selection and fading of resistance mutations in women and infants receiving nevirapine to prevent HIV-1 vertical transmission (HIVNET012).","volume":"15","author":"Eshleman","year":"2001","journal-title":"AIDS"},{"key":"R13-6-20210131","doi-asserted-by":"crossref","first-page":"F111","DOI":"10.1097\/00002030-200007280-00001","article-title":". Identification of the K103N resistance mutation in Ugandan women receiving nevirapine to prevent HIV-1 vertical transmission.","volume":"14","author":"Jackson","year":"2000","journal-title":"AIDS"},{"key":"R14-6-20210131","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1056\/NEJMoa041305","article-title":". Intrapartum exposure to nevirapine and subsequent maternal responses to nevirapine-based antiretroviral therapy.","volume":"351","author":"Jourdain","year":"2004","journal-title":"N Engl J Med"},{"key":"R15-6-20210131","doi-asserted-by":"crossref","first-page":"e4096","DOI":"10.1371\/journal.pone.0004096","article-title":"Nevirapine resistance and breast-milk HIV transmission: effects of single and extended-dose nevirapine prophylaxis in subtype C HIV-infected infants.","volume":"4","author":"Moorthy","year":"2009","journal-title":"PLoS One"},{"key":"R16-6-20210131","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1093\/cid\/cir798","article-title":". IMPAACT P1032 Protocol Team. A comparison of 3 regimens to prevent nevirapine resistance mutations in HIV-infected pregnant women receiving a single intrapartum dose of nevirapine.","volume":"54","author":"Van Dyke","year":"2012","journal-title":"Clin Infect Dis"},{"key":"R19-6-20210131","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1056\/NEJMoa0906768","article-title":". Abacavir-lamivudine versus tenofovir-emtricitabine for initial HIV-1 therapy.","volume":"361","author":"Sax","year":"2009","journal-title":"N Engl J Med"},{"key":"R21-6-20210131","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1056\/NEJMoa051871","article-title":"; for the 934 Study Group. Tenofovir DF, emtricitabine and efavirenz vs. zidovudine, lamivudine and efavirenz for HIV.","volume":"354","author":"Gallant","year":"2006","journal-title":"N Engl J Med"},{"key":"R22-6-20210131","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/S1055-3290(06)60241-0","article-title":". Continuation of postpartum antiretroviral therapy in a cohort of women infected with human immunodeficiency virus.","volume":"13","author":"Tedaldi","year":"2002","journal-title":"J Assoc Nurses AIDS Care"},{"key":"R23-6-20210131","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1097\/00005650-200009000-00005","article-title":". Antiretroviral use and pharmacy-based measurement of adherence in postpartum HIV-infected women.","volume":"38","author":"Turner","year":"2000","journal-title":"Med Care"},{"key":"R24-6-20210131","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1097\/00126334-200207010-00007","article-title":". Prenatal and postpartum zidovudine adherence among pregnant women with HIV: results of a MEMS substudy from the Perinatal Guidelines Evaluation Project.","volume":"30","author":"Ickovics","year":"2002","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R25-6-20210131","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1097\/QAI.0b013e31817bbe80","article-title":". Adherence to antiretrovirals among US women during and after pregnancy.","volume":"48","author":"Bardeguez","year":"2008","journal-title":"J Acquir Immune Defic Syndr"},{"key":"R26-6-20210131","doi-asserted-by":"crossref","first-page":"1863","DOI":"10.1089\/jwh.2009.1880","article-title":"I., Gillani FS, Flanigan TP, et al.. Follow-up care among HIV-infected pregnant women in Mississippi.","volume":"19","author":"Rana","year":"2010","journal-title":"J Womens Health"},{"key":"R28-6-20210131","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1056\/NEJMoa0906626","article-title":". Antiretroviral therapies in women after single-dose nevirapine exposure.","volume":"363","author":"Lockman","year":"2010","journal-title":"N Engl J Med"},{"key":"R29-6-20210131","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1086\/430741","article-title":". Emergence of drug-resistant HIV-1 after intrapartum administration of single-dose nevirapine is substantially underestimated.","volume":"192","author":"Johnson","year":"2005","journal-title":"J Infect Dis"},{"key":"R30-6-20210131","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1086\/430742","article-title":". Sensitive drug-resistance assays reveal long-term persistence of HIV-1 variants with the K103N nevirapine (NVP) resistance mutation in some women and infants after the administration of single-dose NVP: HIVNET 012.","volume":"192","author":"Flys","year":"2005","journal-title":"J Infect Dis"},{"key":"R31-6-20210131","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/QAD.0b013e32832e5303","article-title":". Postpartum antiretroviral drug resistance in HIV-1-infected women receiving pregnancy-limited antiretroviral therapy.","volume":"24","author":"Paredes","year":"2010","journal-title":"AIDS"}],"container-title":["JAIDS Journal of Acquired Immune Deficiency Syndromes"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/QAI.0000000000000072","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,14]],"date-time":"2021-05-14T05:36:55Z","timestamp":1620970615000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00126334-201404150-00006"}},"subtitle":["Week 24 Results of AIDS Clinical Trials Group Protocol A5227"],"short-title":[],"issued":{"date-parts":[[2014,4,15]]},"references-count":25,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2014]]}},"URL":"https:\/\/doi.org\/10.1097\/qai.0000000000000072","relation":{},"ISSN":["1525-4135"],"issn-type":[{"value":"1525-4135","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4,15]]}}}